Latest News Finance

Creative Biolabs Provides Standardized and High-quality Pre-made Oncolytic Virus for Global Clients

 Breaking News
  • No posts were found

Creative Biolabs Provides Standardized and High-quality Pre-made Oncolytic Virus for Global Clients

August 26
12:36 2019

New York, US – August 26, 2019 – As a reliable partner engaged in the immunotherapy field for over 10 years, Creative Biolabs has been committed to providing standardized and high-quality pre-made oncolytic virus for clients all over the world, in which Pre-made Oncolytic Herpes Simplex and Pre-made Oncolytic Vaccinia Virus are two classic types that earns impressive reputation for Creative Biolabs in the industry.

Oncolytic viruses that can selectively replicate in and lyse cancer cells without harming normal cells are qualified enough to become a powerful platform for immunotherapy involving both direct tumor cell lysis and the induction of immunogenic cell death (ICD).  Equipped with an exclusive OncoVirapy™ platform developed by seasoned scientists with professional skills, Creative Biolabs can offer a wide range of pre-made oncolytic viruses including adenovirus (AdV), vesicular stomatitis virus (VSV), herpes simplex virus (HSV), vaccinia virus (VACV) for oncolytic virus therapy research, with an upgraded therapeutic activity in preclinical studies.

Herpes simplex virus (HSV), a human neurogenic dsDNA virus with life-long latent infection of neurons and long-term transgene expression are commonly used for basic research and clinical trials. By combining genomic gene deletion, exogenous gene insertion, capsid modification, miRNA modification, promoter and strains selection, Creative Biolabs develops Pre-made Oncolytic Herpes Simplex Virus characterized by superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector, avoiding evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47. If needed, various transgene especially cytokines can be inserted for the specific clinical needs.

As the most potential live biotherapeutic agent, vaccinia virus (VACV) have been used for in vitro and in vivo studies, and clinical trials. Based on a comprehensive technology platform, scientists at Creative Biolabs strengthen the strong oncolytic efficacy and the powerful antigen presentation capability for a first-class performance in cancer immunotherapy. Pre-made Oncolytic Vaccinia Virus with enhanced tumor-selectivity and antitumor activity, reduced virus virulence, and more efficient immune response, can accommodate more than 30 kb of foreign DNA. Scientists can engineer modified vaccinia viruses to express different immunizing antigens for cancer treatment, including breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, glioblastoma and lung cancer.

In addition to a full list of pre-made oncolytic viruses, Creative Biolabs also utilizes OncoVirapy™ platform to customize oncolytic virus construction services to satisfy all kinds of requirements from global clients. Meanwhile, a comprehensive set of in vitro and in vivo assays are also available to evaluate the oncolytic efficacy and safety of oncolytic virus.

More information can be reached at

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States